The New Front in Pancreatic Cancer Research: Can Amplia Therapeutics Break the Mold? Pancreatic cancer is one of the most feared diagnoses, with mortality rates consistently outpacing incidence.
This year, over 60,000 Americans will be diagnosed, and more than 43,000 will lose their lives to the disease. Against this grim backdrop, medical companies are seeking new approaches to improve outcomes.
Melbourne based Amplia Therapeutics has launched a Phase 2b study on its FAK protein inhibiting drug, narmafotinib, in combination with conventional chemotherapy drugs.